TY - JOUR
T1 - Optimization of PSA screening policies
T2 - A comparison of the patient and societal perspectives
AU - Zhang, Jingyu
AU - Denton, Brian T.
AU - Balasubramanian, Hari
AU - Shah, Nilay D.
AU - Inman, Brant A.
N1 - Funding Information:
Financial support for this study was provided partly by grant CMMI 0844511 from the National Science Foundation.
PY - 2012/3
Y1 - 2012/3
N2 - Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.
AB - Objective. To estimate the benefit of PSA-based screening for prostate cancer from the patient and societal perspectives. Method. A partially observable Markov decision process model was used to optimize PSA screening decisions. Age-specific prostate cancer incidence rates and the mortality rates from prostate cancer and competing causes were considered. The model trades off the potential benefit of early detection with the cost of screening and loss of patient quality of life due to screening and treatment. PSA testing and biopsy decisions are made based on the patient's probability of having prostate cancer. Probabilities are inferred based on the patient's complete PSA history using Bayesian updating. Data Sources. The results of all PSA tests and biopsies done in Olmsted County, Minnesota, from 1993 to 2005 (11,872 men and 50,589 PSA test results). Outcome Measures. Patients' perspective: to maximize expected quality-adjusted life years (QALYs); societal perspective: to maximize the expected monetary value based on societal willingness to pay for QALYs and the cost of PSA testing, prostate biopsies, and treatment. Results. From the patient perspective, the optimal policy recommends stopping PSA testing and biopsy at age 76. From the societal perspective, the stopping age is 71. The expected incremental benefit of optimal screening over the traditional guideline of annual PSA screening with threshold 4.0 ng/mL for biopsy is estimated to be 0.165 QALYs per person from the patient perspective and 0.161 QALYs per person from the societal perspective. PSA screening based on traditional guidelines is found to be worse than no screening at all. Conclusions. PSA testing done with traditional guidelines underperforms and therefore underestimates the potential benefit of screening. Optimal screening guidelines differ significantly depending on the perspective of the decision maker.
KW - PSA
KW - partially observable Markov decision process
KW - patient perspective
KW - prostate cancer
KW - societal perspective
UR - http://www.scopus.com/inward/record.url?scp=84859304024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859304024&partnerID=8YFLogxK
U2 - 10.1177/0272989X11416513
DO - 10.1177/0272989X11416513
M3 - Review article
C2 - 21933990
AN - SCOPUS:84859304024
SN - 0272-989X
VL - 32
SP - 337
EP - 349
JO - Medical Decision Making
JF - Medical Decision Making
IS - 2
ER -